Literature DB >> 27240885

Thyroid cancer.

Maria E Cabanillas1, David G McFadden2, Cosimo Durante3.   

Abstract

Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer-medullary and anaplastic-are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27240885     DOI: 10.1016/S0140-6736(16)30172-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  355 in total

1.  Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.

Authors:  Naoki Oishi; Tetsuo Kondo; Aya Ebina; Yukiko Sato; Junko Akaishi; Rumi Hino; Noriko Yamamoto; Kunio Mochizuki; Tadao Nakazawa; Hiroshi Yokomichi; Koichi Ito; Yuichi Ishikawa; Ryohei Katoh
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

2.  The lncRNA UNC5B-AS1 promotes proliferation, migration, and invasion in papillary thyroid cancer cell lines.

Authors:  Yinghao Wang; Adheesh Bhandari; Jizhao Niu; Fan Yang; Erjie Xia; Zhihan Yao; Yixiang Jin; Zhouci Zheng; Shixu Lv; Ouchen Wang
Journal:  Hum Cell       Date:  2019-02-25       Impact factor: 4.174

3.  Expression of YAP1 in aggressive thyroid cancer.

Authors:  Marilena Celano; Chiara Mignogna; Francesca Rosignolo; Marialuisa Sponziello; Michelangelo Iannone; Saverio Massimo Lepore; Giovanni Enrico Lombardo; Valentina Maggisano; Antonella Verrienti; Stefania Bulotta; Cosimo Durante; Carla Di Loreto; Giuseppe Damante; Diego Russo
Journal:  Endocrine       Date:  2017-01-24       Impact factor: 3.633

Review 4.  Current role of interventional radiology in the management of visceral and bone metastases from thyroid cancer.

Authors:  Roberto Luigi Cazzato; Julien Garnon; Guillaume Koch; Behnam Shaygi; Georgia Tsoumakidou; Jean Caudrelier; Emanuele Boatta; Xavier Buy; Jean Palussiere; Afshin Gangi
Journal:  Gland Surg       Date:  2018-04

5.  Prognosis of patients with TX stage differentiated thyroid cancer: propensity scored matching analysis of the SEER database 2004-2013.

Authors:  Yiquan Xiong; Qiuyang Zhao; Chunping Liu; Shuntao Wang; Zeming Liu; Tao Huang
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

6.  SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.

Authors:  Jing He; Mingxia Zhou; Xiaoyan Li; Siwen Gu; Yun Cao; Tengfei Xing; Wei Chen; Chengyu Chu; Fei Gu; Jian Zhou; Yiting Jin; Jing Ma; Duan Ma; Qiang Zou
Journal:  Oncogene       Date:  2020-01-31       Impact factor: 9.867

7.  Genomic amplification of long noncoding RNA HOTAIRM1 drives anaplastic thyroid cancer progression via repressing miR-144 biogenesis.

Authors:  Ling Zhang; Jin Zhang; Shujing Li; Yanyan Zhang; Yun Liu; Jian Dong; Wenjun Zhao; Bo Yu; Huifang Wang; Jing Liu
Journal:  RNA Biol       Date:  2020-09-20       Impact factor: 4.652

8.  Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.

Authors:  Shu-Fu Lin; Jen-Der Lin; Chun-Nan Yeh; Yu-Tung Huang; Ting-Chao Chou; Richard J Wong
Journal:  Endocr Relat Cancer       Date:  2019-08       Impact factor: 5.678

9.  PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.

Authors:  Katherine D Gray; Jaclyn E McCloskey; Yogindra Vedvyas; Olivia R Kalloo; Steve El Eshaky; Yanping Yang; Enda Shevlin; Marjan Zaman; Timothy M Ullmann; Heng Liang; Dessislava Stefanova; Paul J Christos; Theresa Scognamiglio; Andrew B Tassler; Rasa Zarnegar; Thomas J Fahey; Moonsoo M Jin; Irene M Min
Journal:  Clin Cancer Res       Date:  2020-09-04       Impact factor: 12.531

10.  CircTP53 promotes the proliferation of thyroid cancer via targeting miR-1233-3p/MDM2 axis.

Authors:  W Ma; P Zhao; L Zang; K Zhang; H Liao; Z Hu
Journal:  J Endocrinol Invest       Date:  2020-06-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.